Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WJ-MSCs and Exosomes for Retinitis Pigmentosa
NCT05413148Phase 3Unknown
- Sponsor
- Erciyes University
- Start
- Aug 2022
- Primary completion
- Jul 2023
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of extracellular vesicles derived from Wharton's jelly mesenchymal stem cells in retinitis pigmentosa (RP) (3 arms), sponsored by Erciyes University. Primary endpoints: Best Corrected Visual Acuity Change at 6 months and Visual Field Change at 6 months. Status: unknown.
02
Drugs
extracellular vesicles derived from Wharton's jelly mesenchymal stem cells
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT05413148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05413148.